NCI Perspective on Nanomedicine and Nanobiology Larry Nagahara, Ph.D. Nanotechnology Projects Manager National Cancer Institute Grand Challenges for Nanomedicine and Nanobiology Workshop August 27, 2007

~ 560,000 Americans will die of cancer this year Reference note: Top two bullets are from ACS 2005 Cancer Facts and Figures Chart is from 2003 National Center for Health Statistics ~ 560,000 Americans will die of cancer this year ~1,300,000 Americans will hear the words “you have cancer…” this year ~$185 billion per year on healthcare costs – for cancer in the U.S. alone

We Must Accelerate Progress Against Cancer: Early Diagnostics Is Key Reference note: Top two bullets are from ACS 2005 Cancer Facts and Figures Chart is from 2003 National Center for Health Statistics

NCI Website: http://www.cancer.gov/

NCI Strategic Objectives and Progress To Preempt Cancer at Every Opportunity Understand the Causes and Mechanisms of Cancer Accelerate Progress in Cancer Prevention Improve Early Detection and Diagnosis Develop Effective and Efficient Treatments using Nanotechnology To Ensure the Best Outcomes for All Understand the Factors that Influence Cancer Outcomes Improve the Quality of Cancer Care Improve the Quality of Life for Cancer Patients, Survivors, and Their Families Overcome Cancer Health Disparities

The Potential of Nanotechnology in Cancer Nanotechnology is a “disruptive technology” which will drive a new generation of cancer diagnostic and therapeutic products, resulting in dramatically improved cancer outcomes Early detection – highly sensitive and specific sensors In-vivo imaging – new contrast agents, localization Therapeutics – local, on-particle delivery The Alliance was launched…

NCI Nanotechnology Alliance - Awards Nanotechnology Platform for Pediatric Brain Cancer Imaging and Therapy, University of Washington, Seattle, Wash. Integrated System for Cancer Biomarker Detection, Massachusetts Institute of Technology, Cambridge, Mass. Novel Cancer Nanotechnology Platforms for Photodynamic Therapy and Imaging, Roswell Park Cancer Institute, Buffalo, N.Y. Multifunctional Nanoparticles in Diagnosis and Therapy of Pancreatic Cancer, State University of New York, Buffalo, N.Y. MIT-Harvard Center of Cancer Nanotechnology Excellence, Cambridge, Mass. DNA-linked Dendrimer Nanoparticle Systems for Cancer Diagnosis and Treatment, University of Michigan, Ann Arbor, Mich. Detecting Cancer Early with Targeted Nano-probes for Vascular Signatures, University of California, San Francisco, Calif. Nanotherapeutic Strategy for Multidrug Resistant Tumors, Northeastern University, Boston, Mass. Photodestruction of Ovarian Cancer: ErbB3 Targeted Aptamer-Nanoparticle Conjugate, Massachusetts General Hospital, Boston, Mass. Nanomaterials for Cancer Diagnostics and Therapeutics, Northwestern University, Evanston, Ill. Metallofullerene Nanoplatform for Imaging and Treating Infiltrative Tumor, Virginia Commonwealth University, Richmond, Va. Hybrid Nanoparticles in Imaging and Therapy of Prostate Cancer, University of Missouri, Columbia, Mo. Center for Cancer Nanotechnology Excellence Focused on Therapy Response, Stanford University, Palo Alto, Calif. Nanosystems Biology Cancer Center, California Institute of Technology, Pasadena, Calif. The Siteman Center of Cancer Nanotechnology Excellence at Washington University, St. Louis, Mo. Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer, University of California, San Diego, Calif. Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina, Chapel Hill, N.C. Near-Infrared Fluorescence Nanoparticles for Targeted Optical Imaging University of Texas M. D. Anderson Cancer Center, Houston, Texas Nanotechnology Platform for Targeting Solid Tumors, The Sidney Kimmel Cancer Center, San Diego, Calif. Emory-Georgia Tech Nanotech-nology Center for Personalized and Predictive Oncology, Atlanta, Ga. $145 Million/5 Years (2005-2010) Centers of Cancer Nanotechnology Excellence (8) Cancer Nanotechnology Platform Partnerships (12)

Nanotechnology is an Enabler of New Solutions for Cancer Focus Areas: Molecular imaging and early detection In vivo imaging Reporters of efficacy Multifunctional therapeutics Prevention and control Research enablers Early detection Imaging Therapy

Differentiating the Good, the Bad, & the Ugly protrusion adhesion traction de-adhesion What are the nanomechanics involved in making a cancer cells move? Milan Mrksich - NWU NWU CCNE

The Alliance Website: http://nano.cancer.gov CHECK IT OUT!!! Piotr Grodzinski, Ph.D. Program Director Email: grodzinp@mail.nih.gov Larry Nagahara, Ph.D. Nanotechnology Projects Manager Email:  nagaharl@mail.nih.gov Jerry Lee, Ph.D. Nanotechnology Projects Manager Email: leejerry@mail.nih.gov Office of the Director National Cancer Institute 31 Center Drive MSC 2580 Rm. 10A52 Bethesda, MD 20892-2580 Phone: (301) 496-1550 Fax:     (301) 496-7807

NCI 2008 Budget Request Breakdown New Grants $$$

Some examples of current calls The National Cancer Institute (NCI) is interested in: Early detection of the disease using imaging In vitro early diagnostics: multiplexed sensitive and specific sensors Multi-functional therapeutics and localized therapy delivery Tools and approaches to interrogate, understand, and manipulate single cells, structures, and molecules NIH/CDC Small Business Innovation Research (SBIR) Contract Solicitation Contract proposal receipt date: NOVEMBER 5, 2007 241 Multifunctional Therapeutics Based on Nanotechnology 252 Nanotechnology Imaging and Sensing Platforms for Improved Diagnosis of Cancer